Cogent Biosciences Presents Preclinical Data Highlighting Precision Oncology Pipeline at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Cogent Biosciences, a biotechnology company focused on precision therapies for genetically defined diseases, has announced promising preclinical data from its next-generation selective fibroblast growth factor receptor 2 (FGFR2) program. The data was presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

The company’s internally discovered and developed FGFR2 candidate, CGT4859, has shown strong potency against key primary and resistance driver mutations. It offers potential advantages over covalent approaches, delivering coverage across all known resistance mutations while avoiding FGFR1-mediated toxicity. Additionally, CGT4859 has a reversible profile that may improve tolerability challenges seen with other FGFR2-targeted agents.

Cogent Biosciences plans to initiate clinical trials for CGT4859 in the second half of 2024, pending clearance from the FDA. The company is currently conducting IND-enabling studies for the candidate, positioning it for further development.

The poster presentation at the conference highlighted the identification of CGT4859 as a reversible selective FGFR2 clinical development candidate with potency against gatekeeper and molecular brake mutations. The compound exhibited low nM potency on wild-type FGFR2 and FGFR2 mutations, while also demonstrating selectivity against the kinome and a panel of channels and receptors.

Exploratory pharmacokinetics studies conducted across species showed CGT4859 to be a low-clearance compound with high oral bioavailability. In an AN3 CA model, the candidate demonstrated dose-responsive tumor growth inhibition and was well-tolerated, with complete regressions observed at 5 mg/kg PO.

Cogent Biosciences is committed to developing precision therapies for genetically defined diseases. In addition to the FGFR2 program, the company’s most advanced clinical program is bezuclastinib, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation responsible for driving systemic mastocytosis. The company is also developing a portfolio of novel targeted therapies initially targeting FGFR2 and ErbB2.

With its innovative approach and promising pipeline, Cogent Biosciences is poised to make significant contributions to the field of precision medicine. The company’s dedication to developing therapies for genetically defined diseases underscores its commitment to improving patient outcomes and addressing unmet medical needs.

For more information about Cogent Biosciences and its research programs, visit their website at www.cogentbio.com. Stay updated on the company’s latest developments by following them on Twitter and LinkedIn.